 Home > Medical News > Latest Medical News > "The Lancet" publishes the results of Kexing's new crown vaccine in Turkey

"The Lancet" publishes the results of Kexing's new crown vaccine in Turkey

 Last Update: 2021-07-28
 Source: Internet
 Author: User

Tags

which university

years school lawyer

Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

"The Lancet" publishes the interim results of Kexing's new crown vaccine in Turkey's phase III clinical trial

"The Lancet" published the interim results of Kexingxin crown vaccine in Turkey's phase Ⅲ clinical trial "The Lancet" published the interim results of Kexingxin crown vaccine in Turkey's phase Ⅲ clinical trial

Xinhua News Agency, London, July 8th (Reporter Zhang Jiawei) Researchers have carried out a phase III clinical trial of the new crown inactivated vaccine "Kierlai Fu" developed by Beijing Kexing Zhongwei Biotechnology Co.
, Ltd.
in Turkey
.

The British medical journal "The Lancet" published online the interim analysis results of this trial on the 8th, showing that the relevant effective rate can reach 83.

Researchers from the School of Medicine of the University of Hatchetpe in Turkey participated in this phase III randomized controlled clinical trial, involving more than 10,000 volunteers between 18 and 59 years old
.

During the experiment, part of the volunteers received a placebo, and another part of the volunteers received two doses of "Claireford" 14 days apart

The team's interim analysis of the trial data showed that 14 days after the two doses of the vaccine, the effective rate of preventing symptomatic infections was 83.

According to the paper, "Kierlaifu" can induce a strong antibody response.

However, the team also stated that more research is needed to confirm the long-term efficacy of the vaccine, and that more diverse participants need to be widely included, and the effectiveness of the vaccine against newly emerging variant strains of the new coronavirus needs to be explored

Murat Akova, the corresponding author of the research report and a professor at the School of Medicine of the University of Hatchetpe, said in a statement that one of the advantages of the "Kellyford" vaccine is that it does not need to be stored under extremely low temperature conditions.

According to the "Lancet", "Kierlaifu" has started phase III clinical trials in Brazil, Indonesia, Chile and Turkey since mid-2020

Focus on the new crown pneumonia epidemic

This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.